Boardroom Alpha
Meeting calendar
PSEC · Special meeting · Tuesday, June 9, 2026

Prospect Capital Corp

5 nominees · 1 ballot item.

Renewal of the Company’s authorization, with Board approval, to sell shares of common stock during the next 12 months at prices below then-current NAV per share (subject to conditions, including that sales on any given date do not exceed 25% of outstanding common stock).

Market cap
$1.1B
1Y TSR
-18.5%
Board grade
D
Record date
Mar 11, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026

Follow how the vote landed and what changed on Prospect Capital Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot1

  1. 1

    Renewal of the Company's Authorization, with Approval of its Board of Directors, to Sell Shares of its Common Stock Below NAV

    ManagementBoard: FOR

    Seek stockholder approval to renew authority for the Company, with Board approval, to sell common stock over the next 12 months at prices below the Company’s then-current NAV per share in one or more offerings, subject to conditions (including a limit that shares sold on any given date not exceed 25% of outstanding common stock immediately prior to such sale).

    More detail

    This management proposal asks stockholders to renew a time-limited (12-month) authorization permitting the Company, with the approval of its Board and subject to specified conditions, to sell common shares at prices below the then current NAV per share. Management is seeking approval to preserve flexibility to access equity capital when debt markets are constrained or when market dislocations create attractive investment opportunities that require available capital; the Company also cites the need to manage its asset coverage ratio and capital structure for continued operations and dividend policy. The proposal includes procedural protections: sales below NAV would be limited to no more than 25% of outstanding common stock on any given date and, unless approved by a majority of beneficial holders, would require a majority of independent directors (those with no financial interest) to approve any such sale and to determine in good faith, in consultation with underwriters if applicable, that the sale price closely approximates market value less underwriting discounts. The Board frames the authority as a flexibility tool rather than a commitment to sell at discounts, emphasizing director oversight and prior precedent (other BDCs and the Company’s past use of similar authority). Key risks remain dilution to existing common shareholders, potential erosion of NAV per share, and incentives misalignment because advisor fees would increase with larger asset bases funded by discounted issuances; the proxy discloses illustrative examples of dilutive effects and states there is no maximum discount level. From a governance perspective, the vote can be achieved via two alternate statutory thresholds under the 1940 Act, which creates differing paths to approval and could allow issuance with only director approval of price in some scenarios; this structure affects the degree of direct shareholder protection. For a sophisticated analyst, evaluating the proposal requires weighing the value of optionality to deploy capital in stressed markets against the concrete, immediate dilution risk and the absence of a cap on discount depth; the Board’s requirement of independent director approval and the 25% per-day cap partially mitigate but do not eliminate those concerns. Overall, the Board recommends FOR the renewal, arguing that the strategic benefits of preserved access to capital and the ability to execute opportunistic investments under adverse market conditions outweigh the dilution and fee-related conflicts, with the caveat that directors will exercise judgment and impose conditions on any below-NAV sale.

Director elections

Nominees on the ballot5

Independent
Tenure on this board
17.9 yrs
Also a director at
N/A
Ownership

Top institutional holders10

Latest 13F quarter
1TWO SIGMA INVESTMENTS, LP3.2%15,849,407$41M
2PRIVATE MANAGEMENT GROUP INC2.7%13,535,291$35M
3VAN ECK ASSOCIATES CORP1.5%7,296,734$19M
4MARSHALL WACE, LLP0.9%4,605,610$12M
5UBS Group AG0.8%4,078,915$11M
6Legal General Group Plc0.7%3,640,665$10M
7INDEPENDENT FINANCIAL GROUP, LLC0.7%3,460,351$9M
8MORGAN STANLEY0.5%2,428,678$6M
9GENDELL JEFFREY L0.4%2,027,866$5M
10GENDELL JEFFREY L0.4%1,982,036$5M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Prospect Capital Corp 2026 special meeting?
Prospect Capital Corp (PSEC) holds its 2026 special shareholder meeting on Tuesday, June 9, 2026.
What is the record date for the Prospect Capital Corp 2026 meeting?
The record date for the Prospect Capital Corp 2026 meeting is Wednesday, March 11, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Prospect Capital Corp's 2026 meeting?
The board is presenting 5 director nominees at the Prospect Capital Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Prospect Capital Corp 2026 meeting?
Shareholders will vote on 1 proposal at the Prospect Capital Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer